Health News

Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test

Editor

Health - Purple Foxy Ladies originally published at Health - Purple Foxy Ladies

Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 TestSenzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo's Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market.

PHILADELPHIA - October 27, 2022 - (Newswire.com)

 This contract follows Senzo's recent announcements about the receipt of ISO 13485:2016 certification, and completing a $2 million Pre-Series A financing led by BioAdvance, to apply the ALF technology to other targets such as Flu A/B, Tuberculosis, HIV, C. diff, Sexual Health, and Hepatitis C.

Senzo's core innovation is its Amplified Lateral Flow (ALF) technology which significantly increases the sensitivity of traditional-format lateral flow tests while maintaining specificity. The end result is a fast, low-cost, easy-to-use lateral flow test with the same accuracy as a PCR test, the industry's gold standard test. The ability to incorporate amplification into a lateral flow test has long been a goal for diagnostics test makers but one which has proven difficult to achieve due to the tendency for amplified tests to return false positives. Senzo recently announced results from a blinded, third-party R&D study demonstrating that its Amplified Lateral Flow (ALF) COVID-19 antigen test was 100% accurate in concordance with PCR testing, even in cases with very low viral levels, which could allow for substantially better and earlier detection of virus compared to current lateral flow tests.

"The faster we can accurately diagnose, the sooner we can take action, begin treatment, and the better the patient outcome. Creating a low-cost, user-friendly diagnostic test which delivers PCR accuracy at the point of care, without the need to send a sample to a laboratory, will improve healthcare— it's that simple. BARDA's support of our ALF technology will be instrumental in helping us advance our ultimate goal of bringing ALF tests to market," said Jeremy Stackawitz, CEO of Senzo.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C00041.

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies focussed on enhanced sensitivity, to create mobile, point-of-care, self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products to bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com.


Contact Information:
Alex Mohacs
Sales & Marketing
alex@senzo.com


Press Release Service by Newswire.com

Original Source: Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test

Health - Purple Foxy Ladies originally published at Health - Purple Foxy Ladies

More Stories

DocVA Launches Cutting-Edge Virtual Medical Assistant Services, Revolutionizing Healthcare Operations

DocVA Launches Cutting-Edge Virtual Medical Assistant Services, Revolutionizing Healthcare OperationsBoost Efficiency and Elevate Patient Care With DocVA’s New Virtual Assistant Services


FORT LAUDERDALE, Fla., July 18, 2024 (Newswire.com)
–
DocVA, a leader in the virtual medical assistant staffing industry with years of experience, announces the launch of its comprehensive suite of remote healthcare support services. This innovative offering aims to transform medical practices by providing highly skilled virtual assistants capable of handling various administrative and clinical support tasks.

Virtual Medical Assistant Provider Offers Tailored Solutions to Enhance Patient Care and Streamline Practice Operations

“The world of healthcare is constantly changing, and at DocVA, we’re committed to staying ahead of the curve,” said Nathaniel Barz, CEO of DocVA, who has a decade of experience delivering excellent customer service in the staffing industry. “Our mission is to help as many healthcare practices as possible in the U.S., Canada, and eventually the world by addressing the critical issues that arose post-COVID, such as staff burnout and shortages.”

Comprehensive Virtual Medical Assistant Services

DocVA’s range of services includes:

  • Virtual Medical Receptionist: Handling phone calls, scheduling appointments, managing prescription refill requests, and verifying insurance eligibility
  • Virtual Medical Billing and Insurance Assistant: Managing payments, insurance verification, claims submissions, and pre-authorizations
  • Virtual Medical Assistant: Updating medical records, coordinating with other providers, and fielding patient questions
  • Virtual Medical Scribe: Providing real-time documentation during patient exams, ensuring EMRs stay current

Benefits for All Stakeholders

By partnering with DocVA, healthcare providers can expect:

  • Improved office efficiency and smoother daily operations
  • Enhanced patient satisfaction through elite-level customer service
  • Significant cost savings compared to hiring in-house staff
  • HIPAA-compliant services that ensure patient privacy and data security
  • Flexibility to scale support based on practice needs
  • Reduced staff burnout and improved work-life balance
  • Increased profitability for practices

“Our virtual assistants create a win-win-win situation,” Nathan added. “Staff love it, doctors love it, and patients love it. We’re not just improving healthcare operations but also providing opportunities for people in developing countries to achieve an upper-middle-class lifestyle.”

About DocVA

DocVA is a seasoned virtual medical assistant staffing leader, with two years of specialized experience in the healthcare industry. Our team has placed thousands of virtual medical assistants in different practices across the U.S. Building on lessons learned from previous ventures, DocVA is dedicated to constant improvement and innovation. By leveraging cutting-edge AI technology and a team of highly skilled professionals, DocVA enables medical practices to streamline operations, improve patient care, and reduce operational costs.

Discover more about how DocVA is revolutionizing healthcare support at https://docva.com or contact:

Contact Information:

Nathaniel Barz 

Founder & CEO 

DocVA

clientmanager@docva.com
+1 (954) 304-9702
110 E. Broward Blvd., Suite 1700, Fort Lauderdale, Florida 33312, United States

Contact Information:

Nathaniel Barz

CEO

nbarz@docva.com

+1 (954) 304-9702

Original Source:

DocVA Launches Cutting-Edge Virtual Medical Assistant Services, Revolutionizing Healthcare Operations

Editor